Facilitating Anti-Cancer Combinatorial Drug Discovery by Targeting Epistatic Disease Genes

Area of Science:

• Genetics
• Pharmacology
• Computational Biology

Background:

• Combinatorial drugs offer synergistic effects for complex diseases, but achieving synergy is challenging.
• Interacting disease genes, particularly epistatic genes, represent promising targets for enhancing therapeutic outcomes.
• Synthetic lethality gene pairs in tumors serve as a model for epistatic gene interactions.

Purpose of the Study:

• To investigate the potential of targeting epistatic disease genes for improving combinatorial drug discovery.
• To identify epistatic disease genes and predict synergistic drug combinations.
• To validate the anti-cancer effects of predicted drug combinations and enhance discovery efficiency.

Main Methods:

• Utilized synthetic lethality gene pairs to validate the hypothesis of targeting epistatic genes.
• Employed epistasis detection software on genome-wide association studies (GWAS) data.
• Integrated a three-dimensional (3D) genome-based method for filtering epistatic genes.
• Performed cell cytotoxicity assays to confirm synergistic anti-cancer effects of drug combinations.

Main Results:

• Targeting synthetic lethality gene pairs enriched combinatorial drugs for cancer treatment.
• Identified epistatic disease genes from GWAS data.
• Five predicted drug combinations demonstrated synergistic anti-cancer effects on MCF-7 cells.
• Filtering epistatic genes using 3D genome data improved their disease relevance and combinatorial drug discovery efficiency.

Conclusions:

• Targeting epistatic disease genes is a viable strategy for enhancing combinatorial drug synergy.
• The integration of GWAS, epistasis detection, and 3D genome analysis refines drug target identification.
• This approach significantly improves the efficiency and success rate of discovering effective combinatorial drugs for complex diseases.